SCHEMBL3569702

SCHEMBL3569702

CC1=NN=C(c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3CCN2CCOCC2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ TNKS2 Q9H2K2 1/20 0.38
▸ MCHR1 Q99705 2/20 0.37
▸ CNR2 P34972 4/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CHEK1 O14757 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ CCNB1 P14635 1/20 0.35
▸ WEE1 P30291 1/20 0.35
▸ PTGER4 P35408 1/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569243 0.84 CNR1 (0.38) MAPTCNR2KDM4ENPSR1CNR1
SCHEMBL1338183 0.77 NR5A2 (0.43) MAPTTP53MAPK1HTTATM
SCHEMBL3568345 0.74 CNR1 (0.39) CNR2KDM4ECNR1
Hydrochloric Acid SCHEMBL1340198 0.74 MOK (0.38) MAPTTP53MAPK1HTTATM
SCHEMBL3140076 0.74 MOK (0.38) MAPTTP53MAPK1HTTATM
SCHEMBL3571293 0.73 KDM4E (0.37) CNR2KDM4ECNR1
SCHEMBL1339381 0.72 STAT1 (0.40) MAPTTP53MAPK1MEN1KMT2A
Hydrochloric Acid SCHEMBL1339128 0.72 HTT (0.38) MAPTMAPK1HTTTNKS2CNR2
SCHEMBL3140152 0.72 HTT (0.38) MAPTMAPK1HTTTNKS2CNR2
SCHEMBL3130489 0.71 AR (0.37) MAPK1HTTTNKS2CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
EP-1742947-B1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-08-20 — — EP disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD MAPT 1004/4885TP53 724/4885MAPK1 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback